Separately, Henry Schein named a new independent director, Robert Hombach. Hombach formerly served as chief operations officer and chief financial officer of biopharmaceutical firm Baxalta.

NEW YORK (Reuters) - Activist investor Ananym Capital Management plans to nominate as many as half a dozen directors to the board at Henry Schein, arguing the dental and medical distributor needs ...

Henry Schein (NASDAQ:HSIC ... collaborate with the New York firm to improve shareholder value. Additionally, Robert J. “Bob” Hombach, a former CFO of Baxter (BAX), is also expected to join ...

MELVILLE, N.Y.--(BUSINESS WIRE)-- Henry Schein, Inc. (Nasdaq: HSIC) (“Henry Schein” or the “Company”), the world’s largest provider of health care solutions to office-based dental and ...

Additionally, Robert J. “Bob” Hombach ... As for preliminary financials, Henry Schein (HSIC) reported $3.2B in revenue and $1.19 of non-GAAP net income per diluted share, compared to $3.34B ...